Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Fibrous dysplasia of bone involving only one bone.
5 clinical trials registered, 4 recruiting. Interventions under study include other interventions, drug therapy, and procedural interventions. Pipeline includes 1 PHASE4, 2 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05966064](https://clinicaltrials.gov/study/NCT05966064) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 1:24 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD) |
PHASE4 |
Natasha Appelman-Dijkstra |
RECRUITING |
[NCT07476768](https://clinicaltrials.gov/study/NCT07476768) | PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study | NA | University Hospital, Clermont-Ferrand | UNKNOWN |
[NCT03231644](https://clinicaltrials.gov/study/NCT03231644) | Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry | — | Tovah Burstein | RECRUITING |
[NCT07569731](https://clinicaltrials.gov/study/NCT07569731) | Fibrous Dysplasia: An Epidemiological and Correlational Evaluation of Multimodal Data | — | Istituto Ortopedico Rizzoli | RECRUITING |
[NCT07654647](https://clinicaltrials.gov/study/NCT07654647) | Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction. | NA | Latakia University | RECRUITING |
41 publications have been identified in PubMed for monostotic fibrous dysplasia. Research spans Case Report / Case Series (49%), Review / Meta-Analysis (20%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 20 | 49% |
Research summaries | 8 | 20% |
Disease patterns and progression | 6 | 15% |
Laboratory research | 4 | 10% |
Other research | 1 | 2% |
Clinical study results | 1 | 2% |
New treatment approaches | 1 | 2% |
Best DL (2026). [PMID: 41914823](https://pubmed.ncbi.nlm.nih.gov/41914823/). *J Craniofac Surg*. [Case Report / Case Series]
Saber AY (2026). [PMID: 33085428](https://pubmed.ncbi.nlm.nih.gov/33085428/). *Unknown Journal*. [Review / Meta-Analysis]
Shaw SE (2026). [PMID: 35015466](https://pubmed.ncbi.nlm.nih.gov/35015466/). *Unknown Journal*. [Review / Meta-Analysis]
Giannetti C (2026). [PMID: 41864326](https://pubmed.ncbi.nlm.nih.gov/41864326/). *Ann Endocrinol (Paris)*. [Epidemiology / Natural History]
Levaillant L (2026). [PMID: 42161884](https://pubmed.ncbi.nlm.nih.gov/42161884/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]
Giannetti C (2026). [PMID: 42103580](https://pubmed.ncbi.nlm.nih.gov/42103580/). *Ann Endocrinol (Paris)*. [Epidemiology / Natural History]
Ahmad A (2026). [PMID: 41837037](https://pubmed.ncbi.nlm.nih.gov/41837037/). *International journal of surgery case reports*. [Review / Meta-Analysis]
Xue J (2026). [PMID: 41681790](https://pubmed.ncbi.nlm.nih.gov/41681790/). *Diagnostics (Basel, Switzerland)*. [Review / Meta-Analysis]
Paiva A (2026). [PMID: 41710821](https://pubmed.ncbi.nlm.nih.gov/41710821/). *Cureus*. [Case Report / Case Series]
Tafti D (2026). [PMID: 30422542](https://pubmed.ncbi.nlm.nih.gov/30422542/). *Unknown Journal*. [Review / Meta-Analysis]
AI-curated news mentioning monostotic fibrous dysplasia
Updated Aug 3, 2026
A recent perspective highlights the significant unmet need for effective treatments in fibrous dysplasia and rare pediatric bone diseases. The article discusses current challenges and the necessity for innovative therapeutic approaches.
A new injectable matrix metalloproteinase-responsive nanoparticle hydrogel scaffold has been developed for sustained local drug delivery in fibrous dysplasia. This innovative approach could enhance treatment efficacy for patients with this rare bone disorder.
A preclinical study investigates the effects of anti-RANKL and Zoledronate therapies in a mouse model of fibrous dysplasia. The findings contribute to understanding potential treatment strategies for this rare bone disorder.